investor-governance-director

Investor Home > Corporate Governance > Governance Director

Board of Directors

Board Members

According to the Company's Articles of Incorporation, the Board of Directors shall consist of 5 to 9 directors, each serving a three-year term.

The current Board is composed of seven directors, including four independent directors. The directors possess diverse professional backgrounds spanning business management, biomedical and healthcare industries, finance, law, human resources, auditing, and accounting. Several members also serve as practicing attorneys or university professors, contributing extensive managerial and academic experience that enables the Board to provide well-rounded and professional insights from multiple perspectives.

The composition of the Board reflects the Company's commitment to board diversity. Members bring complementary expertise that helps enhance operational performance and management effectiveness. In addition, the Company values gender equality and has set a target of at least 25% female representation on the Board. Currently, among the seven directors, one is female, representing 14% of the Board. The Company will continue to enhance gender diversity by giving priority consideration to qualified female candidates with the requisite professional competencies and governance expertise during the director nomination process, with the aim of gradually increasing the proportion of female directors.

The principal education and experience of the directors are shown in the table below.

Title	Name	Gender	Education & Experience
Chairman	Eric Wu	Male	B.S. in Industrial Management, Columbia University, USA General Manager, DR.WU Skincare Co., LTd. Deputy Manager, AIG US Investment Co., Ltd. Senior Financial Analyst, PricewaterhouseCoopers LLP
Director	Ying-Chin Wu	Male	National Taiwan University School of Hospital Clinical Professor, National Taiwan University Hospital (NTUH) Founder and Chief Physician, WCLINIC and WSPA
Director	Dr. Wu Investment Holding Co., Ltd. （Representative：Kelly Guo）	Female	Department of Advertising and Public Relations, Fu Jen Catholic University Vice President, DR.WU Skincare Co., Ltd Brand Marketing Director, Taiwan Branch of Shanghai SHAWYA Biotechnology Co., Ltd.
Independent Director	Yuan-Jen Hsu	Male	MBA, The Wharton School, University of Pennsylvania, USA B.S., Columbia University CEO, Yuan Jen Enterprises Director, Hua Nan Financial Holdings Co., Ltd. Vice Chairman, Hua Nan Securities Co., Ltd.
Independent Director	Ching- Yee Lee	Male	MBA, Hitotsubashi University Chief Restructuring Officer, Global Brands Group Director, Branded Lifestyle Holdings Limited President and CEO, KT Licensing Limited CEO, Branded Lifestyle Enterprises Limited Taiwan Branch
Independent Director	Chao-Sheng Chiang	Male	Ph.D. in Law, National Taipei University Associate Professor, Department of Law National Chung-Cheng University Secretary General, Taiwan Law Society of Enterprise Assistant Professor, Tunghai University the College of Law CEO, Corporate Legal Research Center
Independent Director	Huang-Yu Lin	Male	M.S., Columbia University, USA Founder, President and CEO, BlueX Trade Inc., Founder and Chairman, Port Alliance Supply Chain Solutions Co., Ltd. Founder and Chairman, H. SAGA International Co., Ltd.

TOP ↑

Board Performance Evaluation

To strengthen corporate governance and enhance the effectiveness of the Board of Directors, the Company establishes performance objectives to improve the efficiency of Board operations. In accordance with the “Rules for Performance Evaluation of the Board of Directors and Functional Committees”, the Company conducts an internal performance evaluation of the Board of Directors and functional committees annually, and engages an external independent professional institution or a team of external experts and scholars to conduct an evaluation once every three years.

Internal Performance Evaluation

Evaluation Cycle and Period

The Board of Directors shall conduct an annual performance evaluation in accordance with the procedures and indicators set out in the “Rules for Performance Evaluation of the Board of Directors and Functional Committees”. The evaluation results shall be completed before the end of the first quarter of the following year.

Scope and Methodology of Evaluation

Scope of Evaluation: The overall performance of the Board of Directors, individual board members, and functional committees, including the Audit Committee and the Remuneration.

Methods of Evaluation: Internal board self-assessment, individual self-assessment by directors, and peer assessment.

Evaluation Procedures

Board members and members of functional committees conduct self-evaluations using the "Board Performance Self-Evaluation Questionnaire", "Board Member Self-Evaluation Questionnaire", and "Functional Committee Performance Self-Evaluation Questionnaire". The responsible unit then compiles all responses, records the results in accordance with the scoring standards set out in the evaluation rules, and submits the final report to the Board of Directors for review and improvement.

Board Performance Evaluation	Board Member Performance Evaluation	Functional Committee Performance Evaluation
Participation in Company operations. Enhancement of board decision-making quality. Board composition and structure. Election and continuing education of directors. Internal controls.	Understanding of company objectives and missions. Understanding of director responsibilities. Participation in Company operations. Internal relationship management and communication. Professional competence and continuing education. Internal controls.	Participation in Company operations. Understanding of committee responsibilities. Enhancement of committee decision-making quality. Committee composition and member selection. Internal controls.

2025 Evaluation Results

The internal performance evaluation of the Board of Directors and functional committees for 2025 was reported to the Board on March 4, 2026. Based on the evaluations completed by all directors, the Board of Directors and all functional committees were assessed to be operating effectively.

External Performance Evaluation

In October 2025, DR.WU engaged an external professional institution, the Taiwan Association for Board Gobernance, to conduct a Board Governance Effectiveness Evaluation. The evaluation period covered January 1, 2023 to September 30, 2025.

Nomination and Continuing Education, Board Participation in Corporate Operations, Enhancement of Board Decision-Making Quality, Internal Control, Sustainable Development, and Value Creation, with a comprehensive review of the Board’s governance effectiveness and operational performance. The evaluation conclusions and recommendations are summarized as follows:

Key Strengths of Board Governance

Strength	Description
Board structure demonstrates both independence and diversity	Independent directors account for 57% of the Board seats. Directors possess diverse professional backgrounds, contributing multiple perspectives and positively supporting the Company’s long-term stable operations and sustainable development.
Directors actively fulfill their duties	All directors actively participate in meetings and have provided concrete recommendations, including effective utilization of idle funds, proactive revenue generation, and strengthening information security management. Through thorough discussions and exchange of opinions, the Board effectively fulfills its decision-making and supervisory functions.
Strong Board self-discipline	In addition to annual internal self-evaluations of the Board and functional committees, the Company conducts an external performance evaluation every three years. This year marks the first external evaluation, demonstrating the Board’s commitment to continuously enhancing governance effectiveness.
Sound operation of the Audit Committee	In addition to regular Audit Committee meetings, independent directors hold annual communication meetings with the Internal Audit Officer and the Certified Public Accountant, reflecting the Company’s emphasis on internal control and sound corporate governance.
Management compensation linked to sustainability performance	The compensation systems of department managers are clearly linked to sustainability-related performance, effectively supporting the Company’s promotion of environmental protection and social inclusion initiatives.
Strong asset utilization efficiency and cost control	Over the past three years, the Company’s return on equity has exceeded industry peers, demonstrating effective asset utilization and cost control. This performance has supported investments in artificial intelligence, health product projects, and the continued development and expansion of high-potential product lines, earning recognition from the capital market.

Recommendations for Board Governance Improvement

Recommendation	Planned Measures
Include a report on communication with the Internal Audit Officer at the Shareholders' Meeting	Starting from the 2026 Annual General Meeting, a report on communication with the Internal Audit Officer will be added to enhance governance transparency and shareholder communication.
Incorporate succession planning implementation into regular Board reporting	In line with the Company’s overall development strategy and human resource management framework, succession planning for senior management and key talent is being implemented. The Company will evaluate incorporating related outcomes into regular Board reports in due course.
Regularly report sustainability policies and implementation results to the Board and Shareholders’ Meeting	Beginning in 2026, sustainability policies and implementation results will be reported to the Board to strengthen the Board’s supervisory role and enhance transparency of sustainability disclosures.

TOP ↑

Major Board Resolutions

Year	Session	Meeting Date	Major Resolutions
2026	9-11	05.06	Approved the appointment of the Chief Financial Officer, Chief Accounting Officer and Head of Finance. Approved the appointment of the Spokesperson and Corporate Governance Officer. Approved the compensation for the Chief Financial Officer. Approved the allocation ratio of employee compensation to grassroots employees and individual compensation distribution for managers for 2025. Approved the 2026 Q1 Business Report and Financial Statements. Approved the 2026 Q1 Cash Dividend Distribution.
2026	9-10	03.04	Approved the 2025 compensation distribution plan for employees and directors regarding the amount and method of distribution. Approved the 2025 Business Report and Financial Statements. Approved the 2025 Surplus Earnings Distribution. Approved the 2025 Evaluation of the Effectiveness of Internal Control System and Internal Control System Statement. Approved the date, venue, agenda, and shareholder proposal-related matters for the 2026 Annual Shareholders' Meeting. Approved the 2025 performance evaluation results and performance bonus distribution for managers.
2025	9-9	12.17	Approved the Company's 2026 Operating Plan and Budget. Approved the 2026 Audit Plan for the Company and its subsidiaries. Approved the evaluation of the independence and competence of the Company's certifying accountants, as well as the appointment and remuneration of the auditors.
2025	9-8	11.14	Approved the 2025 Q3 Business Report and Financial Statements. Approved the 2025 Q3 Surplus Earnings Distribution. Approved the resolution cash distributed from capital surplus to shareholders. Approved the Amendments to the Company's Rules of Procedure for Board of Directors Meetings Approved the Amendments to the Company's Audit Committee Charter
2025	9-7	08.13	Approved the appointment of the Company's Chief Financial Officer. Approved the appointment of the Company's Spokesperson and Corporate Governance Officer. Approved the 2025 Q2 Surplus Earnings Distribution.
2025	9-6	05.08	Approved the 2025 Q1 Surplus Earnings Distribution.
2025	9-5	03.04	Approved the 2024 compensation distribution plan for employees and directors about the amount and form. Approved Business Report and Financial Statements of 2024. Approved the 2024 Surplus Earnings Distribution. Approved the 2024 Statement on Internal Control System. Approved the Amendment to the Company's Articles of Incorporation. Approved the Amendment to the Internal Control System: Payroll Cycle. Approved the 2024 Shareholders' meeting date, place, agenda and proposal made by shareholders with over 1% share.
2024	9-4	12.11	Approved the 2025 annual budget.
2024	9-3	11.06	Approved the 2024 Q3 Surplus Earnings Distribution. Approved the resolution cash distributed from capital surplus to shareholders.
2024	9-2	08.13	Approved the 2024 Q2 Surplus Earnings Distribution.
2024	9-1	06.05	Approved the election of the chairman. Approved the appointment of the members of the 5th Compensation Committee. Approved to sign a contract with National Chung Cheng University for industry-academic cooperation and academic feedback mechanism.
2024	8-16	05.15	Approved the 2024 Q1 Surplus Earnings Distribution.
2024	8-15	03.13	Approved the 2023 compensation distribution plan for employees and directors about the amount and form. Approved Business Report and Financial Statements of 2023. Approved the 2023 Surplus Earnings Distribution. Approved the 2023 Statement on Internal Control System. Approved the re-elections of directors (inculding independent directors). Approved the propose of candidates for directors (including independent directors) to be nominated by the Board of Directors. Approved the 2024 Shareholders’meeting date, place, agenda and proposal made by shareholders with over 1% share.
2023	8-14	12.13	Approved the 2024 annual budget.
2023	8-13	11.07	Approved the 2023 Q3 Surplus Earnings Distribution. Approved the resolution cash distributed from capital surplus to shareholders. Approved the Risk Management Policy and Procedures.
2023	8-12	08.10	Approved the 2023 Q2 Surplus Earnings Distribution.
2023	8-11	05.09	Approved the 2023 Q1 Surplus Earnings Distribution.
2023	8-10	03.08	Approved the 2022 compensation distribution plan for employees and directors about the amount and form. Approved Business Report and Financial Statements of 2022. Approved the 2022 Surplus Earnings Distribution. Approved the 2022 Statement on Internal Control System. Approved the 2023 Shareholders’meeting date, place, agenda and proposal made by shareholders with over 1% share.
2022	8-9	12.21	Approved the 2023 annual budget.
2022	8-8	11.02	Approved the 2022 Q3 Surplus Earnings Distribution.
2022	8-7	08.12	Approved the 2022 Q2 Surplus Earnings Distribution.
2022	8-6	05.11	Approved the 2022 Q1 Surplus Earnings Distribution. Approved the Appointment of Head of Governance.
2022	8-5	03.09	Approved the 2021 compensation distribution plan for employees and directors about the amount and form. Approved Business Report and Financial Statements of 2021. Approved the 2021 Surplus Earnings Distribution. Approved the 2021 Statement on Internal Control System. Approved the 2022 Shareholders’meeting date, place, agenda and proposal made by shareholders with over 1% share.
2021	8-4	12.22	Approved the 2022 annual budget.
2021	8-3	11.11	Approved the 2021 Q3 Surplus Earnings Distribution.
2021	8-2	08.11	Approved the 2021 Q2 Surplus Earnings Distribution.
2021	8-1	07.07	Approved the election of the chairman. Approved the appointment of the members of the 4th Compensation Committee. Approved to sign a contract with National Chung Cheng University for industry-academic cooperation and academic feedback mechanism.
2021	7-21	06.17	Approved the postponed 2021 Shareholders’ meeting date and place due to the Pandemic.
2021	7-20	05.07	Approved the 2021 Q1 Surplus Earnings Distribution. Approved the resolution cash distributed from capital surplus to shareholders.
2021	7-19	03.05	Approved the 2020 compensation distribution plan for employees and directors about the amount and form. Approved Business Report and Financial Statements of 2020. Approved the 2020 Surplus Earnings Distribution. Approved the 2020 Statement on Internal Control System. Approved the 2021 Shareholders’meeting date, place, agenda and proposal. Approved the 2021 Shareholders’meeting date, place, agenda and proposal made by shareholders with over 1% share.
2020	7-18	12.18	Approved the 2021 annual budget.
2020	7-17	11.10	Approved subsidiary Wclinic Biotechnology Corporation(Samoa) disposal of shares in Jiangsu DR. WU Cosmetics Co., Ltd.
2020	7-16	11.06	Approved the 2020 Q3 Surplus Earnings Distribution.
2020	7-15	10.23	Approved subsidiary Wclinic Biotechnology Corporation, it plans to invest in the establishment of an overseas BVI subsidiary.
2020	7-14	08.07	Approved the 2020 Q2 Surplus Earnings Distribution.
2020	7-13	05.06	Approved the 2020 Q1 Surplus Earnings Distribution.
2020	7-12	03.13	Approved the 2019 compensation distribution plan for employees and directors about the amount and form. Approved Business Report and Financial Statements of 2019. Approved the 2019 Surplus Earnings Distribution. Approved the 2019 Statement on Internal Control System. Approved the 2020 Shareholders’meeting date, place, agenda and proposal made by shareholders with over 1% share.
2019	7-11	12.24	Approved the 2020 annual budget. Approved the 2020 auditing plans for the Company and its subsidiary. Approved the 2019 evaluation of the CPA’s independence and suitability. Approved the resolution cash distributed from capital surplus to shareholders. Approved the amendment to “Articles of Incorporation. Approved the 2020 First extraordinary general meeting date and place.
2019	7-10	11.07	Reported the third quarter 2019 consolidated financial statements. Approved the subsidiary Wclinic Biotechnology capital reduction to cover losses.
2019	7-9	08.06	Reported the second quarter 2019 consolidated financial statements. Approved the amendment to the "Operational Procedures for Loaning of Company Funds. Approved the amendment to the "Operational Procedures for Endorsements and Guarantees. Approved the amendment to the "Policies and systems for compensation of the directors and functional committees. Approved the subsidiary Wclinic Biotechnology capital reduction to cover losses. Approved the subsidiary Wclinic Biotechnology capital reduction and return to parent company.
2019	7-8	05.09	Reported the first quarter 2019 consolidated financial statements. Approved the appointment of managers.
2019	7-7	02.26	Approved the 2018 compensation distribution plan for employees and directors about the amount and form. Approved Business Report and Financial Statements of 2018. Approved the 2018 Deficit Compensated. Approved the 2018 Statement on Internal Control System. Approved the amendment to the Operational Procedures for Acquisition and Disposal of Assets. Approved the change of business place of the Company. Approved the 2019 Shareholders’meeting date, place, agenda and proposal made by shareholders with over 1% share. Approved the resolution cash distributed from capital surplus to shareholders.
2018	7-6	12.24	Approved the investment of Dr. Wu Skincare (Jiangsu) Co., Ltd. Approved the equity disposal of Dr. Wu Skincare (Shanghai) Co., Ltd.
2018	7-5	12.13	Approved the 2019 annual budget. Approved the 2019 auditing plans for the Company and its mainland subsidiary Dr. Wu Skincare (Shanghai) Co., Ltd. Approved the 2018 evaluation of the CPA’s independence and suitability.
2018	7-4	11.08	Approved the application for Complaint Procedures. Approved the accounts receivable are restated as other accounts receivable considered as fund loaning. Approved the compensation for the CFO.
2018	7-3	09.20	Approved the increase in capital for Dr. Wu Skincare (Shanghai) Co., Ltd.
2018	7-2	08.13	Approved the appointment members of the third session of compensation committee. Approved the accounts receivable are restated as other accounts receivable considered as fund loaning.
2018	7-1	06.21	Approved Mr. Eric Wu as Chairman.
2018	6-22	05.10	Approved the appointment of the CFO. Approved the appointment of the Internal Audit Manager. Approved the record date of capital reduction for the cancellation of treasury shares. Approved the accounts receivable-related party are restated as other accounts receivable. Approved the submission of examination of nominated directors (including independent directors) candidate list to board of directors. Approved the exemption from non-compete clause for new directors (including independent directors).
2018	6-21	03.08	Approved the 2017 compensation distribution plan for employees and directors about the amount and form. Approved Business Report and Financial Statements of 2017. Approved the 2017 Surplus Earnings Distribution. Approved the 2017 Statement on Internal Control System. Approved the loan to the Company’s subsidiary Dr. Wu Skincare (Shanghai) Co., Ltd. Approved the accounts receivable-related party are restated as other accounts receivable, shall be recognized as fund loaning. Approved the re-elections of directors (inculding independent directors). Approved the propose of candidates for directors (including independent directors) to be nominated by the Board of Directors. Approved the 2018 Shareholders’meeting date, place, agenda and proposal made by shareholders with over 1% share.
2018	6-20	01.10	Approved the repurchasing of Company’s stocks.
2017	6-19	12.14	Approved the 2018 annual budget. Approved the 2018 auditing plans for the Company and its mainland subsidiary Dr. Wu Skincare (Shanghai) Co., Ltd. Approved the 2017 evaluation of the CPA’s independence and suitability.
2017	6-18	11.09	Reported the Third quarter 2017 consolidated financial statements. Approved the amendments to Audit Committee Charter、Rules of Procedure for Board of Directors Meetings and Rules Governing the Scope of Powers of Independent Directors. Approved the Company’s subsidiary Dr.Wu Skincare (Shanghai) Co., Ltd. investment to set up subsidiary.
2017	6-17	08.10	Reported the second quarter 2017 consolidated financial statements. Approved the change of business place of the Company.
2017	6-16	03.10	Approved the Company’s ex-dividend-date. Approved the appointment of a deputy G.M.
2017	6-15	03.10	Reported the first quarter 2017 consolidated financial statements. Approved the evaluation of the list of nominated candidates for directors to the Board. Approved the 2016 compensation distribution plan for managers.
2017	6-14	03.10	Approved the 2016 compensation distribution plan for employees and directors about the amount and form. Approved Business Report and Financial Statements of 2016. Approved the 2016 Surplus Earnings Distribution. Approved the 2016 Statement on Internal Control System. Approved the amendments to the Settlement Procedures for the Acquisition and Disposal of Assets. Approved the loan to the Company’s subsidiary Dr. Wu Skincare (Shanghai) Co., Ltd. Approved the Company's cooperation with Price Waterhouse Coopers (PwC) Taiwan for auditor rotation. Approved the by-election of one director and the proposed candidates for directors to be nominated by the Board of Directors. Approved the 2017 Shareholders’meeting date, place, agenda and proposal made by shareholders with over 1% share.
2016	6-13	12.19	Approved the 2017 annual budget. Approved the 2016 auditing plans for the Company and its mainland subsidiary Dr. Wu Skincare (Shanghai) Co., Ltd. Approved the 2016 evaluation of the CPA's independence and suitability. Approved the appointment of the CFO. Approved the compensation for the CFO.
2016	6-12	11.07	Reported the third quarter 2016 consolidated financial statements. Approved the increase in capital for Dr. Wu Skincare (Shanghai) Co., Ltd.
2016	6-11	08.08	Reported the second quarter 2016 consolidated financial statements.
2016	6-10	05.20	Approved the appointment of a deputy financial director.
2016	6-9	05.12	Approved the Company’s ex-rights date, ex-dividend-date and capital increase date. Approved the appointment of managers. Approved the compensation for managers. Approved the 2015 compensation distribution plan for managers. Approved the issuance of new shares through cash distribution to managers before listing on the OTC market.
2016	6-8	03.07	Approved the 2015 compensation distribution plan (i.e. amount and form) for employees and directors. Approved the 2015 Business Report and Financial Statements. Approved the 2015 Statement on Internal Control System. Approved the 2015 Surplus Earnings Distribution. Approved the Issuance of New Common Shares for Capital Increase through Retained Earnings. Approved the Issuance of New Common Shares for Capital Increase through Cash. Approved the change of CFO and spokesperson. Approved the loan to subsidiary Dr. Wu Skincare (Shanghai) Co., Ltd. Approved the application for suspension and resumption of trading procedures. Approved the new agenda and amendments to the 2016 Shareholders’ Meeting.
2016	6-7	01.21	Approved the 2016 Shareholders’ meeting date, place, agenda and proposal made by shareholders with over 1% share.

TOP ↑

Investor Home